Ted White - 24 Aug 2023 Form 4/A - Amendment Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
24 Aug 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
06 Feb 2025, 16:15:07 UTC
Date Of Original Report
28 Aug 2023
Previous filing
25 Jul 2023
Next filing
16 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Award $0 +150,000 +116% $0.000000 278,789 24 Aug 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.
F2 The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.